Search Results

You are looking at 151 - 160 of 292 items for :

  • "Neoadjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Penile Cancer

Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Matthew C. Biagioli, Mario A. Eisenberger, Richard E. Greenberg, Harry W. Herr, Brant A. Inman, Deborah A. Kuban, Timothy M. Kuzel, Subodh M. Lele, Jeff Michalski, Lance Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Donald L. Trump, Geoffrey Wile, Timothy G. Wilson, Mary Dwyer, and Maria Ho

has resectable metastatic adenopathy, although recent studies would favor a neoadjuvant chemotherapy approach followed by surgical consolidation. 82 , 83 Generally, the procedure follows the primary tumor treatment by 4 to 6 weeks. Again during this

Full access

Cervical Cancer

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, David K. Gaffney, Robert L. Giuntoli II, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, Mark A. Morgan, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole R. McMillian, and Miranda Hughes

without distant metastases, recommended treatment is extended-field RT (including pelvic and para-aortic lymph nodes) with concurrent cisplatin-based chemotherapy and with (or without) brachytherapy. Although neoadjuvant chemotherapy followed by surgery

Full access

Role of Repeat Resection in Non–Muscle-Invasive Bladder Cancer

Harry W. Herr

bladder-sparing strategies. Lastly, patients who have muscle-invasive tumor on repeat TUR require aggressive therapy, such as neoadjuvant chemotherapy and cystectomy. Failure to detect locally invasive bladder cancer may have devastating consequences for

Full access

Combined Modality Therapy of Localized Gastric and Esophageal Cancers

Prajnan Das, Norio Fukami, and Jaffer A. Ajani

: 1727 – 1733 . 49. Urschel JD Vasan H Blewett CJ . A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer . Am J Surg 2002 ; 183 : 274 – 279

Full access

Involving Family and Social Support Systems in Tobacco Cessation Treatment for Patients With Cancer

The Cancer Center Cessation Initiative Family and Social Support Systems Working Group

: 543 – 552 . 10.1177/1359105309355338 20460411 2. Aprilianto E , Lumadi SA , Handian FI . Family social support and the self-esteem of breast cancer patients undergoing neoadjuvant chemotherapy . J Public Health Res 2021 ; 10

Full access

Taxanes in the Adjuvant Treatment of Breast Cancer

Donna Trauth and Lori J. Goldstein

– 40 . 70 Mamounas EP . Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies . Semin Oncol 1998 ; 25 ( Suppl 3 ): 31 – 35 . 71 NSABP . The effect on primary tumor response of adding sequential

Full access

Successful Resection After Neoadjuvant Therapy in Pancreatic Adenocarcinoma

Parvin F. Peddi and Andrea Wang-Gillam

after neoadjuvant chemotherapy . J Clin Oncol 2010 ; 28 : 375 – 379 . 14 Kim R Byer J Saif MW . BRCA and pancreatic cancer: selection of chemotherapy . JOP 2012 ; 13 : 180 – 181 . 15 Huang J Robertson JM Margolis J . Long

Full access

Ovarian Cancer Biomarkers: Current Options and Future Promise

Christine M. Coticchia, Jiang Yang, and Marsha A. Moses

epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking . Gynecol Oncol 2007 ; 105 : 712 – 715 . 15. Moore RG Brown AK Miller MC . The use of multiple novel tumor biomarkers for the

Full access

PET in Cervical Cancer — Implications for `Staging,' Treatment Planning, Assessment of Prognosis, and Prediction of Response

Michael A. Gold

cancer . Lancet Oncol 2000 ; 1 : 106 . 48. Yoshida Y Kurokawa T Kawahara K . Metabolic monitoring of advanced uterine cervical cancer neoadjuvant chemotherapy by using [F-18]-fluorodeoxyglucose positron emission tomography: preliminary

Full access

Time for More Inclusive Cancer Trials

Piet Dirix, Lynda Wyld, Shani Paluch-Shimon, and Philip Poortmans

, Wang Y , Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices . J Natl Compr Canc Netw 2015 ; 13 : 1383 – 1393 . 10.6004/jnccn.2015